The United Kingdom has approved another antibody treatment called sotrovimab for people with Covid that cuts the risk of severe illness.
Scientists say preliminary checks suggest it should work well even against new variants such as Omicron.
The drug, given in a drip into a vein, binds to the virus to stop it entering the cells. In a clinical trial, a single dose reduced the risk of hospitalisation and death by 79 percent in high-risk adults. It is reportedly the second drug of its kind – a monoclonal antibody treatment – that UK regulators have approved.